CEL-SCI CORP (CVM)
US1508376076 - Common Stock
Overall CVM gets a fundamental rating of 1 out of 10. We evaluated CVM against 602 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CVM has reported negative net income.
CVM had a negative operating cash flow in the past year.
In the past 5 years CVM always reported negative net income.
CVM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -104.68%, CVM is not doing good in the industry: 80.43% of the companies in the same industry are doing better.
CVM's Return On Equity of -228.76% is on the low side compared to the rest of the industry. CVM is outperformed by 74.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -104.68% | ||
| ROE | -228.76% | ||
| ROIC | N/A |
ROA(3y)-65.85%
ROA(5y)-77.07%
ROE(3y)-111.8%
ROE(5y)-692579%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, CVM has more shares outstanding
CVM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CVM has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -20.40, we must say that CVM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -20.40, CVM is not doing good in the industry: 90.47% of the companies in the same industry are doing better.
CVM has a Debt/Equity ratio of 0.70. This is a neutral value indicating CVM is somewhat dependend on debt financing.
CVM's Debt to Equity ratio of 0.70 is on the low side compared to the rest of the industry. CVM is outperformed by 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.4 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CVM has a Current Ratio of 1.46. This is a normal value and indicates that CVM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.46, CVM is not doing good in the industry: 85.28% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that CVM should not have too much problems paying its short term obligations.
The Quick ratio of CVM (1.06) is worse than 87.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
CVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.04%, which is quite good.
EPS 1Y (TTM)9.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q17.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 12.82% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.67%
EPS Next 2Y18.18%
EPS Next 3Y16.06%
EPS Next 5Y12.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CVM. In the last year negative earnings were reported.
Also next year CVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CVM's earnings are expected to grow with 16.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.18%
EPS Next 3Y16.06%
5. Dividend
5.1 Amount
CVM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CEL-SCI CORP
NYSEARCA:CVM (11/30/2023, 4:44:42 PM)
After market: 2.2 -0.05 (-2.22%)2.25
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)12-26 2023-12-26/bmo
Inst Owners11.33%
Inst Owner Change-1.15%
Ins Owners5.06%
Ins Owner Change0.59%
Market Cap106.33M
Analysts80
Price Target8.67 (285.33%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.81%
Min EPS beat(2)-16.96%
Max EPS beat(2)-10.66%
EPS beat(4)1
Avg EPS beat(4)-4.11%
Min EPS beat(4)-16.96%
Max EPS beat(4)15.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.19 | ||
| P/tB | 7.28 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -104.68% | ||
| ROE | -228.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-65.85%
ROA(5y)-77.07%
ROE(3y)-111.8%
ROE(5y)-692579%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.59% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | -20.4 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)181.85%
Cap/Depr(5y)114.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)9.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q17.83%
EPS Next Y16.67%
EPS Next 2Y18.18%
EPS Next 3Y16.06%
EPS Next 5Y12.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.06%
EBIT Next 3Y132.7%
EBIT Next 5Y111.21%
FCF growth 1Y15.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.29%
OCF growth 3YN/A
OCF growth 5YN/A